S-Adenosyl-L-methionine tosylate
(Synonyms: AdoMet, SAM, SAMe) 目录号 : GC61259
S-Adenosyl-L-methioninetosylate(S-Adenosylmethioninetosylate)是通过蛋氨酸腺苷转移酶的作用由蛋氨酸和ATP内源性生产的，是一种重要的具有口服活性的甲基供体。S-Adenosyl-L-methioninetosylate是一种具有有效的抗抑郁和镇痛作用的膳食补充剂，并可用于肝病和骨关节炎的研究。
Cas No.:52248-03-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
S-Adenosyl-L-methionine tosylate (S-Adenosyl methionine tosylate) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor. S-Adenosyl-L-methionine tosylate is a dietary supplement with potent antidepressant and analgesic effects, and has the potential for liver disease and osteoarthritis research[1][2][3].
S-Adenosyl-L-methionine (Ademetionine) is involved in three main metabolic pathways: 1) methylation, as the principal source of methyl groups in the body; 2) transsulfuration, S-Adenosyl-L-methionine forms S-Adenosylhomocysteine (SAH) and then converted to homocysteine (Hcy) which can be converted to cystathionine then to cysteine and the sulfate (SO4) donated to other metabolic intermediates; and 3) aminopropylation, as S-Adenosyl-L-methionine plays an important role in the synthesis of polyamines which can eventually form and recycle methionine[2].In vitro studies using human articular chondrocytes have shown S-Adenosyl-L-methionine-induced increases in proteoglycan synthesis and proliferation rates in rabbits[2].
Mice lacking methionine adenosyltransferase 1a (Mat1a) have reduced hepatic S-Adenosyl-L-methionine levels and develop oxidative stress, steatohepatitis, and hepatocellular carcinoma (HCC). However, injury and HCC also occur if hepatic S-Adenosyl-L-methionine level is excessive chronically. Thus a normal hepatic S-Adenosyl-L-methionine level is necessary to maintain liver health and prevent injury and HCC[3].
[1]. G M Bressa. et al. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14. [2]. Wadie I Najm, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004 Feb 26;5:6. [3]. Shelly C Lu, et al. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct;92(4):1515-42.
| Cas No. | 52248-03-0 | SDF | |
| 别名 | AdoMet, SAM, SAMe | ||
| Canonical SMILES | O[C@@H]([C@H]([C@H](N1C=NC2=C1N=CN=C2N)O3)O)[C@H]3C[S+](CC[C@H](N)C([O-])=O)C.CC4=CC=C(S(=O)(O)=O)C=C4 | ||
| 分子式 | C22H30N6O8S2 | 分子量 | 570.64 |
| 溶解度 | Water: 250 mg/mL (438.10 mM) | 储存条件 | -20°C, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7524 mL | 8.7621 mL | 17.5242 mL |
| 5 mM | 0.3505 mL | 1.7524 mL | 3.5048 mL |
| 10 mM | 0.1752 mL | 0.8762 mL | 1.7524 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine
J Clin Psychopharmacol 2004 Dec;24(6):661-4.PMID:15538131DOI:10.1097/01.jcp.0000145339.45794.cd.
Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-Adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.